基本信息来源于合作网站,原文需代理用户跳转至来源网站获取       
摘要:
Objective:To study the pharmacological mechanism of Guanxin Ⅱ formula(冠心Ⅱ号方,GX Ⅱ)for treatment of coronary heart disease(CHD).Methods:A network pharmacology-based method was utilized.First candidate compounds,targets of GX Ⅱ were collected using PharmMapper,BATMAN-TCM,DrugBank and SwissTargetPrediction,and targets on CHD were mined from GeneCards,DisGenet,DrugBank and GEO.Afterwards,the big hub compounds and targets were chosen in the candidate compounds-direct therapeutic targets on the CHD(C-T)network and the direct therapeutic targets on the CHD(T-D)network.Furthermore,the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis were performed to identify the enriched terms.Finally,a molecular docking simulation strategy was adopted to verify the binding capacity between the big hub compounds and big hub targets on CHD.Results:First,114 candidate compounds were selected with the following criteria:OB≥30%,DL≥0.18,and HL ≥4 h.Then,1,035 targets of GX Ⅱ were gathered,while 928 targets on CHD were collected.Afterwards,196 common targets of compound targets and therapeutic targets on CHD were defined as direct therapeutic targets acting on CHD.In addition,the contribution index(CI)in the C-T network was calculated,and 4 centrality properties,including degree,betweenness,closeness and coreness,in the T-D network,4 big hub compounds,and 6 big hub targets were eventually chosen.Furthermore,the GO and KEGG analysis indicated that GX Ⅱ acted on CHD by regulating the reactive oxygen species metabolism,steroid metabolism,lipid metabolism,inflammatory response,proliferation,differentiation and apoptosis.The docking results manifested excellent binding capacity between the 4 big hub compounds and 6 big hub targets on CHD.Conclusion:This network pharmacology-based exploration revealed that GX Ⅱ might prevent and inhibit the primary pathological processes of CHD.
推荐文章
冠心Ⅱ号方联合西药治疗老年冠心病42例
冠心病
中西医结合疗法
冠心Ⅱ号方
消心痛
阿替洛尔
冠心病进展相关基因筛选及冠心Ⅱ号方干预靶点的预测
急性心肌梗死
稳定型冠心病
冠心Ⅱ号方
转录组
干预靶点
基因筛选
冠心Ⅱ号系列方对大鼠心肌梗死的实验研究
心肌梗死/中医药疗法
活血祛瘀剂/药理学
活血祛瘀剂/治疗应用
大鼠
冠心Ⅴ号合剂改善急性心肌梗死后心室重构的研究进展
急性心肌梗死
冠心Ⅴ号合剂
心室重构,进展
内容分析
关键词云
关键词热度
相关文献总数  
(/次)
(/年)
文献信息
篇名 Network Pharmacology-Based Exploration of Synergistic Mechanism of Guanxin Ⅱ Formula(冠心Ⅱ号方)for Coronary Heart Disease
来源期刊 中国结合医学杂志(英文版) 学科
关键词
年,卷(期) 2021,(2) 所属期刊栏目 Original Articles
研究方向 页码范围 106-114
页数 9页 分类号
字数 语种 英文
DOI 10.1007/s11655-020-3199-z
五维指标
传播情况
(/次)
(/年)
引文网络
引文网络
二级参考文献  (0)
共引文献  (0)
参考文献  (34)
节点文献
引证文献  (0)
同被引文献  (0)
二级引证文献  (0)
1997(1)
  • 参考文献(1)
  • 二级参考文献(0)
2002(1)
  • 参考文献(1)
  • 二级参考文献(0)
2004(1)
  • 参考文献(1)
  • 二级参考文献(0)
2007(1)
  • 参考文献(1)
  • 二级参考文献(0)
2008(1)
  • 参考文献(1)
  • 二级参考文献(0)
2009(1)
  • 参考文献(1)
  • 二级参考文献(0)
2010(1)
  • 参考文献(1)
  • 二级参考文献(0)
2012(2)
  • 参考文献(2)
  • 二级参考文献(0)
2013(1)
  • 参考文献(1)
  • 二级参考文献(0)
2014(2)
  • 参考文献(2)
  • 二级参考文献(0)
2015(1)
  • 参考文献(1)
  • 二级参考文献(0)
2016(6)
  • 参考文献(6)
  • 二级参考文献(0)
2017(7)
  • 参考文献(7)
  • 二级参考文献(0)
2018(4)
  • 参考文献(4)
  • 二级参考文献(0)
2019(4)
  • 参考文献(4)
  • 二级参考文献(0)
2021(0)
  • 参考文献(0)
  • 二级参考文献(0)
  • 引证文献(0)
  • 二级引证文献(0)
引文网络交叉学科
相关学者/机构
期刊影响力
中国结合医学杂志(英文版)
月刊
1672-0415
11-4928/R
大16开
北京西苑操场1号
82-825
1995
eng
出版文献量(篇)
2643
总下载数(次)
0
  • 期刊分类
  • 期刊(年)
  • 期刊(期)
  • 期刊推荐
论文1v1指导